Xeris Selling General Administrative vs Research Development Analysis

XERS Stock

USD 3.35 0.19 5.37%

Xeris Pharmaceuticals financial indicator trend analysis is more than just analyzing Xeris Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Xeris Pharmaceuticals is a good investment. Please check the relationship between Xeris Pharmaceuticals Selling General Administrative and its Research Development accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xeris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.

Selling General Administrative vs Research Development

Selling General Administrative vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Xeris Pharmaceuticals Selling General Administrative account and Research Development. At this time, the significance of the direction appears to have very week relationship.

The correlation between Xeris Pharmaceuticals' Selling General Administrative and Research Development is 0.27. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Research Development in the same time period over historical financial statements of Xeris Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Xeris Pharmaceuticals' Selling General Administrative and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of Xeris Pharmaceuticals are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Selling General Administrative i.e., Xeris Pharmaceuticals' Selling General Administrative and Research Development go up and down completely randomly.

Correlation Coefficient

0.27

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Selling General Administrative

Research Development

Most indicators from Xeris Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Xeris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xeris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.At this time, Xeris Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 458.6 M in 2025, whereas Tax Provision is likely to drop (1.2 M) in 2025.

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	12.7M	13.2M	15.1M	15.9M
Interest Income	2.6M	4.8M	5.5M	5.7M

Depreciation And Amortization Interest Income

Xeris Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity
Total Assets		0.91	0.9	0.57	0.94	-0.5	0.93	0.85	0.85	-0.96	0.8	0.87	0.91	0.37	0.79	0.74	0.85	0.91	0.88	0.95	0.89	0.92	0.99	0.9	0.82	0.78
Other Current Liab	0.91		1.0	0.37	0.97	-0.63	0.99	0.9	0.97	-0.96	0.96	0.75	0.99	0.49	0.91	0.62	0.97	0.94	0.98	0.9	0.9	0.84	0.91	0.99	0.95	0.67
Total Current Liabilities	0.9	1.0		0.36	0.95	-0.61	0.99	0.88	0.98	-0.95	0.96	0.72	0.98	0.5	0.93	0.61	0.98	0.93	0.98	0.88	0.9	0.83	0.9	0.99	0.97	0.68
Total Stockholder Equity	0.57	0.37	0.36		0.47	0.34	0.4	0.51	0.34	-0.53	0.22	0.53	0.34	-0.12	0.21	0.89	0.27	0.54	0.33	0.29	0.66	0.59	0.6	0.29	0.25	0.61
Other Liab	0.94	0.97	0.95	0.47		-0.58	0.98	0.88	0.9	-0.96	0.9	0.86	0.97	0.48	0.81	0.69	0.89	0.93	0.92	0.91	0.89	0.84	0.91	0.96	0.85	0.68
Net Tangible Assets	-0.5	-0.63	-0.61	0.34	-0.58		-0.64	-0.37	-0.52	0.52	-0.58	-0.56	-0.7	-0.61	-0.69	0.08	-0.65	-0.41	-0.66	-0.72	-0.27	-0.46	-0.42	-0.7	-0.64	-0.11
Property Plant And Equipment Net	0.93	0.99	0.99	0.4	0.98	-0.64		0.88	0.95	-0.96	0.93	0.81	0.99	0.52	0.91	0.63	0.96	0.93	0.98	0.91	0.89	0.86	0.91	0.99	0.94	0.67
Current Deferred Revenue	0.85	0.9	0.88	0.51	0.88	-0.37	0.88		0.9	-0.93	0.85	0.62	0.82	0.17	0.75	0.75	0.82	0.95	0.84	0.77	0.96	0.85	0.9	0.85	0.82	0.76
Net Debt	0.85	0.97	0.98	0.34	0.9	-0.52	0.95	0.9		-0.93	0.97	0.6	0.93	0.42	0.91	0.6	0.97	0.93	0.96	0.82	0.91	0.79	0.88	0.95	0.97	0.68
Retained Earnings	-0.96	-0.96	-0.95	-0.53	-0.96	0.52	-0.96	-0.93	-0.93		-0.88	-0.8	-0.94	-0.34	-0.84	-0.75	-0.9	-0.97	-0.93	-0.91	-0.95	-0.91	-0.97	-0.94	-0.88	-0.76
Accounts Payable	0.8	0.96	0.96	0.22	0.9	-0.58	0.93	0.85	0.97	-0.88		0.57	0.93	0.56	0.86	0.48	0.94	0.86	0.92	0.81	0.83	0.69	0.81	0.94	0.92	0.63
Cash	0.87	0.75	0.72	0.53	0.86	-0.56	0.81	0.62	0.6	-0.8	0.57		0.81	0.4	0.63	0.66	0.66	0.72	0.73	0.85	0.68	0.79	0.79	0.78	0.61	0.56
Non Current Assets Total	0.91	0.99	0.98	0.34	0.97	-0.7	0.99	0.82	0.93	-0.94	0.93	0.81		0.59	0.92	0.56	0.96	0.89	0.98	0.91	0.84	0.83	0.88	0.99	0.94	0.62
Non Currrent Assets Other	0.37	0.49	0.5	-0.12	0.48	-0.61	0.52	0.17	0.42	-0.34	0.56	0.4	0.59		0.51	-0.13	0.51	0.19	0.51	0.45	0.17	0.27	0.27	0.52	0.49	0.12
Other Assets	0.79	0.91	0.93	0.21	0.81	-0.69	0.91	0.75	0.91	-0.84	0.86	0.63	0.92	0.51		0.44	0.98	0.81	0.98	0.81	0.77	0.81	0.79	0.93	0.99	0.56
Cash And Short Term Investments	0.74	0.62	0.61	0.89	0.69	0.08	0.63	0.75	0.6	-0.75	0.48	0.66	0.56	-0.13	0.44		0.52	0.8	0.57	0.52	0.87	0.73	0.78	0.57	0.5	0.79
Net Receivables	0.85	0.97	0.98	0.27	0.89	-0.65	0.96	0.82	0.97	-0.9	0.94	0.66	0.96	0.51	0.98	0.52		0.89	0.99	0.85	0.84	0.81	0.85	0.97	1.0	0.63
Common Stock Total Equity	0.91	0.94	0.93	0.54	0.93	-0.41	0.93	0.95	0.93	-0.97	0.86	0.72	0.89	0.19	0.81	0.8	0.89		0.9	0.83	0.98	0.85	0.93	0.91	0.87	0.76
Common Stock Shares Outstanding	0.88	0.98	0.98	0.33	0.92	-0.66	0.98	0.84	0.96	-0.93	0.92	0.73	0.98	0.51	0.98	0.57	0.99	0.9		0.88	0.86	0.86	0.88	0.98	0.99	0.64
Non Current Liabilities Total	0.95	0.9	0.88	0.29	0.91	-0.72	0.91	0.77	0.82	-0.91	0.81	0.85	0.91	0.45	0.81	0.52	0.85	0.83	0.88		0.77	0.85	0.91	0.91	0.82	0.67
Capital Surpluse	0.89	0.9	0.9	0.66	0.89	-0.27	0.89	0.96	0.91	-0.95	0.83	0.68	0.84	0.17	0.77	0.87	0.84	0.98	0.86	0.77		0.87	0.94	0.85	0.83	0.82
Other Current Assets	0.92	0.84	0.83	0.59	0.84	-0.46	0.86	0.85	0.79	-0.91	0.69	0.79	0.83	0.27	0.81	0.73	0.81	0.85	0.86	0.85	0.87		0.93	0.82	0.81	0.75
Other Stockholder Equity	0.99	0.91	0.9	0.6	0.91	-0.42	0.91	0.9	0.88	-0.97	0.81	0.79	0.88	0.27	0.79	0.78	0.85	0.93	0.88	0.91	0.94	0.93		0.87	0.83	0.82
Total Liab	0.9	0.99	0.99	0.29	0.96	-0.7	0.99	0.85	0.95	-0.94	0.94	0.78	0.99	0.52	0.93	0.57	0.97	0.91	0.98	0.91	0.85	0.82	0.87		0.95	0.64
Property Plant And Equipment Gross	0.82	0.95	0.97	0.25	0.85	-0.64	0.94	0.82	0.97	-0.88	0.92	0.61	0.94	0.49	0.99	0.5	1.0	0.87	0.99	0.82	0.83	0.81	0.83	0.95		0.62
Preferred Stock Total Equity	0.78	0.67	0.68	0.61	0.68	-0.11	0.67	0.76	0.68	-0.76	0.63	0.56	0.62	0.12	0.56	0.79	0.63	0.76	0.64	0.67	0.82	0.75	0.82	0.64	0.62

Click cells to compare fundamentals

Xeris Pharmaceuticals Account Relationship Matchups

Xeris Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	109.0M	159.2M	344.5M	322.6M	371.0M	203.3M
Other Current Liab	25.1M	70.1M	65.9M	80.1M	92.2M	96.8M
Total Current Liabilities	27.3M	28.2M	73.6M	95.2M	109.5M	114.9M
Total Stockholder Equity	14.4M	33.8M	45.2M	(6.8M)	(7.8M)	(7.4M)
Other Liab	8.9M	10.2M	42.0M	29.2M	33.6M	35.3M
Net Tangible Assets	14.4M	33.8M	(59.1M)	(98.3M)	(88.5M)	(84.0M)
Property Plant And Equipment Net	7.9M	6.7M	28.4M	29.2M	33.6M	35.2M
Net Debt	38.8M	49.4M	76.1M	161.7M	186.0M	195.3M
Retained Earnings	(246.2M)	(337.4M)	(554.8M)	(617.0M)	(555.3M)	(527.6M)
Accounts Payable	3.1M	8.9M	4.6M	11.6M	13.3M	14.0M
Cash	19.5M	37.6M	122.0M	67.4M	77.6M	67.2M
Non Current Assets Total	21.5M	6.9M	157.7M	166.3M	191.3M	200.9M
Non Currrent Assets Other	(13.0M)	4.7M	267K	4.5M	5.2M	5.5M
Other Assets	420K	232K	829K	4.7M	5.4M	5.7M
Cash And Short Term Investments	75.5M	133.8M	122.0M	72.5M	83.3M	98.0M
Net Receivables	6.9M	17.5M	30.8M	39.2M	45.1M	47.3M
Liabilities And Stockholders Equity	109.0M	159.2M	344.5M	322.6M	371.0M	203.3M
Non Current Liabilities Total	67.2M	97.2M	225.7M	234.2M	269.3M	143.7M
Other Current Assets	3.2M	4.6M	9.3M	5.8M	6.6M	4.3M
Other Stockholder Equity	371.1M	555.4M	600.0M	610.3M	701.8M	357.4M
Total Liab	94.6M	125.4M	299.3M	329.4M	378.8M	397.7M
Property Plant And Equipment Gross	6.7M	10.8M	28.4M	35.2M	40.5M	42.5M
Total Current Assets	87.5M	152.2M	186.8M	156.3M	179.7M	132.6M
Accumulated Other Comprehensive Income	43K	6K	(23K)	(25K)	(28.8K)	(30.2K)
Common Stock	2K	3K	6K	14K	16.1K	16.9K
Property Plant Equipment	7.9M	6.7M	6.6M	9.5M	10.9M	11.5M
Net Invested Capital	120.8M	183.3M	232.3M	184.2M	211.8M	132.4M
Net Working Capital	124.0M	63.6M	113.2M	61.1M	70.2M	89.4M
Short Long Term Debt Total	58.3M	87.0M	198.1M	229.2M	263.6M	148.6M
Long Term Debt	87.0M	88.1M	187.1M	190.9M	219.6M	117.9M
Short Term Investments	96.2M	35.2M	0.0	5.0M	4.5M	4.3M
Capital Stock	3K	6K	13K	14K	16.1K	9.5K
Non Current Liabilities Other	3.5M	30.2M	25.7M	6.2M	7.2M	14.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Xeris Stock Analysis

When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC